New data presented at the International Papillomavirus Conference reinforces the evidence for the sensitivity and specificity of Hologic’s aptima HPV assay.
Evidence at the conference in Cape Town included poster presentations that highlighted the strong longitudinal clinical performance of Aptima HPV to give women and healthcare professionals the safety and confidence they deserve.
There was preliminary data of a study determining the five- to six-year longitudinal negative predictive value of the Aptima HPV test in a routine screening population in Germany.
It demonstrated a non-inferior longitudinal performance of the RNA-based Aptima HPV test in comparison to the gold-standard DNA-based HC2 test.
hologic.com
